Express Scripts Holding Co

Express Scripts — Caremark RX — Proxy Contest (January 2007)

23 slides from Express Scripts's proxy contest presentation, Jan 16, 2007

  1. Slide 1: Delivering Superior Value to Stockholders, Plan Sponsors and Patients

    January 16, 2007 Delivering Superior Value to Stockholders Plan Sponsors and Patients

  2. Slide 2: Safe Harbor: Forward Looking Statements

    Safe Harbor: Forward Looking Statements This presentation contains "forward-looking statements," including, among other statements, statements regarding the proposed business combination between Express Scripts and Caremark, and the anticipated consequences and benefits of such transaction. Statemen

  3. Slide 3: Safe Harbor: Additional Information

    Safe Harbor: Additional Information Express Scripts has filed a preliminary proxy statement in connection with Caremark's special meeting of stockholders at which the Caremark stockholders will consider the CVS Merger Agreement and matters in connection therewith. Express Scripts stockholders are st

  4. Slide 4: Transaction Update

    Transaction Update Express Scripts launching a $25 billion Exchange Offer to acquire Caremark, which will deliver superior value to stockholders Fully committed financing provided by Citigroup and Credit Suisse Filed for HSR approval and confident that regulatory requirements will be met in a timely

  5. Slide 5: Setting the Record Straight

    Setting the Record Straight Hyper competitive marketplace 3-year contracts industry norm Thus 1/3 of business "at risk" every year Caremark's supposed retention headaches unrelated to proposed transaction Recent claim The facts "Caremark would lose $8 billion in revenues"

  6. Slide 6: Setting the Record Straight: Client Retention

    Setting the Record Straight ESRX Client Retention 90% 91% 93% Willingness to Recommend ESRX 90% 94% 94% Client Satisfaction with ESRX 94% 97% 96% 2005 2006 Recent claim "Caremark would lose $8 billion in revenues" In past 3 years, twice as many CMX clients have moved to ESRX than vice versa 2004

  7. Slide 7: Setting the Record Straight

    Setting the Record Straight "NGC stands firm that they made the right choice coming to ESI." - Northrop Grumman Corporation, former CMX client "We are excited to be with ESI and are looking forward to a strong and lasting relationship." - The ServiceMaster Company, former CMX client "Express Scripts

  8. Slide 8: Setting the Record Straight: Acquisition Track Record

    Setting the Record Straight (at closing) 4.0x $715 MM $460 MM $466 MM $333 MM $1,268 MM Shouldn't $25 billion of value be in the hands of someone who can not only optimize operations, but can also optimize the cost of capital 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006E ROIC 0.161 0.125 0.095

  9. Slide 9: Setting the Record Straight: Significant Financial Flexibility

    Setting the Record Straight Significant Financial Flexibility Note: Based on Company estimates and Wall Street research. (1) EBITDA includes expected synergies. 2006E pro forma EBITDA greater than $2.7 billion before synergies Assumes share repurchases and capital expenditures (from each of ESRX and

  10. Slide 10: Regulatory Review: Competitive Landscape

    Regulatory Review Competitive Landscape More than 40 PBMs compete today. In addition to Medco, Caremark and Express Scripts, there are: Large insurance companies such as Aetna, Cigna, Humana, Independence Blue Cross, Kaiser, United Health, Wellpoint and others Large retail pharmacy chains including

  11. Slide 11: What About CMX Stockholders?

    What About CMX Stockholders? CVS/CMX transaction was presented as Merger of Equals with little or no takeover premium for CMX stockholders CMX treating break-up fee as cost of due diligence instead of cost of consummating the deal In the face of clearly superior proposal from ESRX, Board of Director

  12. Slide 12: Delivering Superior Value to Stockholders

    Delivering Superior Value to Stockholders Express Scripts' Superior Proposal ESRX Proven Strategic Rationale ESRX Proven Financial Performance ESRX Proven Track Record

  13. Slide 13: Why Independence and Alignment Win

    Why Independence and Alignment Win Lowering client costs is dependent upon engaging the consumer and fostering competition among suppliers Lowering plan sponsor costs through Active Management Driving to lowest cost depends on Using generics and lower cost brands over higher cost brands Using more c

  14. Slide 14: Why Independence and Alignment Win

    Retail Mail Call Ctr Touches 30000 273000 168000 Why Independence and Alignment Win We significantly outperformed the market in moving share - one patient at a time Lipitor Crestor Vytorin Generics* ESRX -0.22 0.0515 0.0454 0.123 National -0.087 0.022 0.025 0.04 * Represents the portion of Lipitor s

  15. Slide 15: Conflicts Inherent to Integration with Retail

    Conflicts Inherent to Integration with Retail Retail Drug choice Drug utilization Channel choice Overall retail discounts Fundamental business model A CVS / CMX model that doesn't place the customer first will always lose Likely to be biased towards higher priced drugs Maximize number of fills Biase

  16. Slide 16: Horizontal Wins Over Vertical

    Horizontal Wins Over Vertical (1) Transaction Value for target at closing. Vertical PBM Transactions Have Failed to Create Stockholder Value Lilly 1994 Rite Aid 1999 Advance 2000 SmithKline 1994 ESRX 1999 Merck 1993 Spin-off 2003 Change in Value - - 63% - - 34% - - 70% 21% (2% APR) AVG LOSS IN VALUE

  17. Slide 17: Horizontal Wins Over Vertical

    Horizontal Wins Over Vertical Horizontal PBM transactions create significant value, while vertical PBM transactions destroy value Vertical PBM Transactions Have Failed to Create Stockholder Value Lilly 1994 Rite Aid 1999 Advance 2000 SmithKline 1994 ESRX 1999 Merck 1993 Spin-off 2003 Change in Value

  18. Slide 18: Value Loss on CVS Proposal

    Value Loss on CVS Proposal (1) Based on value paid for PBM business compared to value received at disposal (2) CVS / CMX deal consideration CVS firm value $31B - - $9B CMX firm value $24B CVS firm value $31B CMX $15B As shown, the four non-aligned deals destroyed 36% (1) of value on average 36% of C

  19. Slide 19: Horizontal Transactions Win for ESRX Stockholders

    Horizontal Transactions Win for ESRX Stockholders * Rx growth reflects PBMs as configured today Successful acquisitions and strong organic growth drive increased stockholder value $715 MM $460 MM $466 MM $333 MM $1,268 MM Claims Growth* ESRX 11.9% 5.4% 8.1% 8.8% CMX 10.1% 0.1% 3.7% -5.0% Note: Stock

  20. Slide 20: Express Scripts' Unique Perspective of Caremark

    Express Scripts' Unique Perspective of Caremark Numerous discussions beginning in 2001 between ESRX and CMX Due diligence discussions quantifying potential synergies via third parties (including consultants' input) Deep understanding of client mix and business model Complementary skill sets will dri

  21. Slide 21: Significant Synergy Benefits

    Significant Synergy Benefits Our synergy estimates are sound and based on demonstrated opportunities BASELINE: $500M Lower mail pharmacy costs Lower retail pharmacy costs Lower specialty pharmacy costs Better manufacturer discounts Lower SG&A Lower direct processing costs Two consulting firms ESRX's

  22. Slide 22: Superior Currency

    Superior Currency Express Scripts has dramatically outperformed CVS over the last ten years Express Scripts CVS $1,531 $315 Note: Includes dividend reinvestment. Stock prices through December 15, 2006. Ending Value $100 investment S&P 500 $193

  23. Slide 23: Express Scripts Historical Forward P/E

    Express Scripts Historical Forward P/E Express Scripts is trading at a significant discount to historical P/Es

Caremark RX — Proxy Contest (January 2007) on 6ix